Enrollment open for new immune response study

Health experts believe the vaccine will work for people who are immunocompromised, but they say need more data to be sure
Local hospitals have precautions in place to stop a Legionnaires’ disease outbreak

MADISON, Wis (WKBT) – A new study is being formed to study the immune response for people who have taken the COVID-19 vaccine.

The study is specifically looking to study how the vaccines have affected people with inflammatory bowel disease or IBD.

IBD affects about 1.3% of adults in the United States.

The term covers two conditions, Crohn’s disease, and ulcerative colitis.

Both are characterized by chronic inflammation of the gastrointestinal tract.

Patients with IBD are often given immunosuppressants and by definition are immunocompromised.

Some of the treatments may increase the risk of a severe outcome from COVID-19, which is why experts say the study is important.

“Our study is taking patients with Crohn’s and Ulcerative colitis, who are getting the Covid vaccine, and we’re gonna check blood work over a year to make sure that they’re protected,” said Dr. Freddy Caldera a Gastrointestinal Physician at UW School of Medicine and Public Health.

Health experts believe the vaccine will work for people who are immunocompromised, but they say need more data to be sure.